Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRG neoadjuvant and adjuvant Keytruda with Stupp protocol in newly diagnosed GBM
2024-517535-52-00Phase 4Authorised
- Sponsor
- Medical University of Silesia
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pembrolizumab in glioblastoma (GBM) (2 arms), sponsored by Medical University of Silesia. Primary endpoints: Safety and tolerability and Patient-reported quality of life and health status. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-517535-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517535-52-00.